However, until now drug development for many targets in, for example, asthma — including, IL-5, IL-4 and TSLP — has not been driven mainly by the use of GWAS data, despite supporting genetic data being known to increase the likelihood of a drug reaching market18. This evidence concerns the gene IL5 and asthma.